Regencell Bioscience (NASDAQ:RGC) Shares Up 32% – Time to Buy?

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) rose 32% on Wednesday . The company traded as high as $33.00 and last traded at $33.5680. Approximately 202,455 shares traded hands during mid-day trading, a decline of 50% from the average daily volume of 405,187 shares. The stock had previously closed at $25.43.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Regencell Bioscience Price Performance

The firm’s 50-day moving average price is $27.10 and its 200 day moving average price is $21.73.

Institutional Investors Weigh In On Regencell Bioscience

Large investors have recently bought and sold shares of the stock. Squarepoint Ops LLC purchased a new position in Regencell Bioscience during the second quarter worth $1,701,000. Geode Capital Management LLC lifted its position in shares of Regencell Bioscience by 5,637.5% in the second quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock valued at $6,664,000 after acquiring an additional 384,250 shares in the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Regencell Bioscience during the fourth quarter valued at $92,000. Vident Advisory LLC boosted its stake in shares of Regencell Bioscience by 65.7% during the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after acquiring an additional 11,866 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new stake in Regencell Bioscience during the 2nd quarter worth about $768,000. Institutional investors and hedge funds own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.